Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Mesenchymal Stem/Stromal Cell Engulfment Reveals Metastatic Advantage in Breast Cancer.

Chen YC, Gonzalez ME, Burman B, Zhao X, Anwar T, Tran M, Medhora N, Hiziroglu AB, Lee W, Cheng YH, Choi Y, Yoon E, Kleer CG.

Cell Rep. 2019 Jun 25;27(13):3916-3926.e5. doi: 10.1016/j.celrep.2019.05.084.

2.

A reproducible scaffold-free 3D organoid model to study neoplastic progression in breast cancer.

Djomehri SI, Burman B, Gonzalez ME, Takayama S, Kleer CG.

J Cell Commun Signal. 2019 Mar;13(1):129-143. doi: 10.1007/s12079-018-0498-7. Epub 2018 Dec 4.

3.

Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations.

Jiagge E, Jibril AS, Davis M, Murga-Zamalloa C, Kleer CG, Gyan K, Divine G, Hoenerhoff M, Bensenhave J, Awuah B, Oppong J, Adjei E, Salem B, Toy K, Merajver S, Wicha M, Newman L.

J Glob Oncol. 2018 Oct;4:1-8. doi: 10.1200/JGO.18.00056.

PMID:
30307804
4.

Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates.

East EG, Carter CS, Kleer CG.

Arch Pathol Lab Med. 2018 Oct;142(10):1182-1185. doi: 10.5858/arpa.2018-0221-RA. Review.

PMID:
30281370
5.

CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.

McMullen ER, Gonzalez ME, Skala SL, Tran M, Thomas D, Djomehri SI, Burman B, Kidwell KM, Kleer CG.

Breast Cancer Res Treat. 2018 Dec;172(3):577-586. doi: 10.1007/s10549-018-4960-2. Epub 2018 Sep 15.

PMID:
30220054
6.

p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis.

Anwar T, Arellano-Garcia C, Ropa J, Chen YC, Kim HS, Yoon E, Grigsby S, Basrur V, Nesvizhskii AI, Muntean A, Gonzalez ME, Kidwell KM, Nikolovska-Coleska Z, Kleer CG.

Nat Commun. 2018 Jul 18;9(1):2801. doi: 10.1038/s41467-018-05078-8.

7.

Ethnic disparity in breast cancer survival in southern Thai women.

Virani S, Wetzel EC, Laohawiriyakamol S, Boonyaphiphat P, Geater A, Kleer CG, Pang J, Rentschler KM, Colacino JA, de Leon CFM, Rozek LS, Sriplung H.

Cancer Epidemiol. 2018 Jun;54:82-89. doi: 10.1016/j.canep.2018.02.007. Epub 2018 Apr 21.

PMID:
29684800
8.

Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas.

Tran MN, Kleer CG.

J Cell Commun Signal. 2018 Mar;12(1):13-19. doi: 10.1007/s12079-018-0451-9. Epub 2018 Jan 22. Review.

9.

Mesenchymal Stem Cell-Induced DDR2 Mediates Stromal-Breast Cancer Interactions and Metastasis Growth.

Gonzalez ME, Martin EE, Anwar T, Arellano-Garcia C, Medhora N, Lama A, Chen YC, Tanager KS, Yoon E, Kidwell KM, Ge C, Franceschi RT, Kleer CG.

Cell Rep. 2017 Jan 31;18(5):1215-1228. doi: 10.1016/j.celrep.2016.12.079.

10.

MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.

Martin EE, Huang W, Anwar T, Arellano-Garcia C, Burman B, Guan JL, Gonzalez ME, Kleer CG.

Oncogene. 2017 Apr 20;36(16):2275-2285. doi: 10.1038/onc.2016.381. Epub 2016 Nov 7.

11.

Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.

Asirvatham JR, Falcone MM, Kleer CG.

Arch Pathol Lab Med. 2016 Oct;140(10):1045-51. doi: 10.5858/arpa.2016-0238-RA. Review.

PMID:
27684975
12.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

13.

Dual roles of CCN proteins in breast cancer progression.

Kleer CG.

J Cell Commun Signal. 2016 Sep;10(3):217-222. Epub 2016 Aug 12.

14.

Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates.

Zhang Y, Kleer CG.

Arch Pathol Lab Med. 2016 Jul;140(7):665-71. doi: 10.5858/arpa.2016-0042-RA. Review.

PMID:
27362571
15.

Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.

Zhang Y, Liss AL, Chung E, Pierce LJ, Kleer CG.

Breast Cancer Res Treat. 2016 Jul;158(1):21-28. doi: 10.1007/s10549-016-3853-5. Epub 2016 Jun 11.

PMID:
27290698
16.

Chronic Mastitis in Egypt and Morocco: Differentiating between Idiopathic Granulomatous Mastitis and IgG4-Related Disease.

Allen SG, Soliman AS, Toy K, Omar OS, Youssef T, Karkouri M, Ayad E, Abdel-Aziz A, Hablas A, Tahri A, Oltean HN, Kleer CG, Merajver SD.

Breast J. 2016 Sep;22(5):501-9. doi: 10.1111/tbj.12628. Epub 2016 Jun 8.

17.

The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells.

Huang W, Martin EE, Burman B, Gonzalez ME, Kleer CG.

Oncotarget. 2016 May 3;7(18):25180-93. doi: 10.18632/oncotarget.7734.

18.

Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.

Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC.

Am J Transl Res. 2015 Jun 15;7(6):1009-20. eCollection 2015.

19.

Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.

Toy KA, Valiathan RR, Núñez F, Kidwell KM, Gonzalez ME, Fridman R, Kleer CG.

Breast Cancer Res Treat. 2015 Feb;150(1):9-18. doi: 10.1007/s10549-015-3285-7. Epub 2015 Feb 10.

20.

Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA.

Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.

21.

A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies.

Dudley DT, Li XY, Hu CY, Kleer CG, Willis AL, Weiss SJ.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14882-7. doi: 10.1073/pnas.1410996111. Epub 2014 Sep 29.

22.

Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.

Pang JC, Virani NK, Kidwell KM, Kleer CG.

J Cell Commun Signal. 2014 Sep;8(3):211-8. doi: 10.1007/s12079-014-0240-z. Epub 2014 Aug 19.

23.

Re-excision rates of invasive ductal carcinoma with lobular features compared with invasive ductal carcinomas and invasive lobular carcinomas of the breast.

Arps DP, Jorns JM, Zhao L, Bensenhaver J, Kleer CG, Pang JC.

Ann Surg Oncol. 2014 Dec;21(13):4152-8. doi: 10.1245/s10434-014-3871-7. Epub 2014 Jul 1.

PMID:
24980090
24.
25.

SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.

Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H.

Oncogene. 2015 Feb 5;34(6):671-80. doi: 10.1038/onc.2014.4. Epub 2014 Feb 17.

26.

EZH2 expands breast stem cells through activation of NOTCH1 signaling.

Gonzalez ME, Moore HM, Li X, Toy KA, Huang W, Sabel MS, Kidwell KM, Kleer CG.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103. doi: 10.1073/pnas.1308953111. Epub 2014 Feb 10.

27.

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity.

Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA, Weinberg RA.

Cell. 2013 Jul 3;154(1):61-74. doi: 10.1016/j.cell.2013.06.005.

28.

EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.

Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK.

Cell Cycle. 2013 Jul 1;12(13):2042-50. doi: 10.4161/cc.25065. Epub 2013 Jun 6.

29.

Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer.

Anwar TE, Kleer CG.

Hum Pathol. 2013 Aug;44(8):1457-64. doi: 10.1016/j.humpath.2013.01.005. Epub 2013 Apr 8. Review.

30.

EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG.

Breast Cancer Res Treat. 2013 Apr;138(3):741-52. doi: 10.1007/s10549-013-2498-x. Epub 2013 Mar 29.

31.

Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.

Arps DP, Healy P, Zhao L, Kleer CG, Pang JC.

Breast Cancer Res Treat. 2013 Apr;138(3):719-26. doi: 10.1007/s10549-013-2493-2. Epub 2013 Mar 28.

32.

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS.

Cancer Res. 2013 Mar 1;73(5):1635-46. doi: 10.1158/0008-5472.CAN-12-3349. Epub 2013 Feb 26.

34.

Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.

Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG, Weiss SJ.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16654-9. doi: 10.1073/pnas.1205822109. Epub 2012 Sep 24.

35.

Inflammatory breast cancer in north Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco.

Soliman AS, Kleer CG, Mrad K, Karkouri M, Omar S, Khaled HM, Benider AL, Ayed FB, Eissa SS, Eissa MS, McSpadden EJ, Lo AC, Toy K, Kantor ED, Xiao Q, Hampton C, Merajver SD.

Breast Dis. 2011-2012;33(4):159-69. doi: 10.3233/BD-2012-000337.

36.

Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.

Schwartz T, Stark A, Pang J, Awuah B, Kleer CG, Quayson S, Kingman S, Aitpillah F, Abantanga F, Jiagge E, Oppong JK, Osei-Bonsu E, Martin I, Yan X, Toy K, Adjei E, Wicha M, Newman LA.

Cancer. 2013 Feb 1;119(3):488-94. doi: 10.1002/cncr.27737. Epub 2012 Aug 28.

37.

RhoC impacts the metastatic potential and abundance of breast cancer stem cells.

Rosenthal DT, Zhang J, Bao L, Zhu L, Wu Z, Toy K, Kleer CG, Merajver SD.

PLoS One. 2012;7(7):e40979. doi: 10.1371/journal.pone.0040979. Epub 2012 Jul 23.

38.

Metaplastic carcinomas of the breast: diagnostic challenges and new translational insights.

Rungta S, Kleer CG.

Arch Pathol Lab Med. 2012 Aug;136(8):896-900. doi: 10.5858/arpa.2012-0166-CR.

39.

CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer.

Pal A, Huang W, Li X, Toy KA, Nikolovska-Coleska Z, Kleer CG.

Cancer Res. 2012 Sep 15;72(18):4818-28. doi: 10.1158/0008-5472.CAN-12-0154. Epub 2012 Jul 17.

40.

Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.

Pang J, Toy KA, Griffith KA, Awuah B, Quayson S, Newman LA, Kleer CG.

Breast Cancer Res Treat. 2012 Aug;135(1):59-66. doi: 10.1007/s10549-012-2055-z. Epub 2012 Apr 13.

41.

Discoidin domain receptor tyrosine kinases: new players in cancer progression.

Valiathan RR, Marco M, Leitinger B, Kleer CG, Fridman R.

Cancer Metastasis Rev. 2012 Jun;31(1-2):295-321. doi: 10.1007/s10555-012-9346-z. Review.

42.

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.

Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM.

Nat Med. 2011 Nov 20;17(12):1646-51. doi: 10.1038/nm.2580.

43.

Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition.

Zhang Y, Toy KA, Kleer CG.

Mod Pathol. 2012 Feb;25(2):178-84. doi: 10.1038/modpathol.2011.167. Epub 2011 Nov 11.

44.

p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.

Rosenthal DT, Iyer H, Escudero S, Bao L, Wu Z, Ventura AC, Kleer CG, Arruda EM, Garikipati K, Merajver SD.

Cancer Res. 2011 Oct 15;71(20):6338-49. doi: 10.1158/0008-5472.CAN-11-1291. Epub 2011 Aug 23.

45.

On how CCN6 suppresses breast cancer growth and invasion.

Huang W, Pal A, Kleer CG.

J Cell Commun Signal. 2012 Mar;6(1):5-10. doi: 10.1007/s12079-011-0148-9. Epub 2011 Aug 13.

46.

Survival of inflammatory breast cancer patients compared to non-inflammatory breast cancer patients in Egypt.

Spencer B, Banerjee M, Omar S, Khaled H, Anwar N, Zaghloul MS, Eissa S, Kleer CG, Dey S, Merajver SD, Soliman AS.

Breast J. 2011 Sep-Oct;17(5):545-7. doi: 10.1111/j.1524-4741.2011.01146.x. Epub 2011 Aug 9. No abstract available.

47.

Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.

Alford SH, Toy K, Merajver SD, Kleer CG.

Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.

48.

CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer.

Lorenzatti G, Huang W, Pal A, Cabanillas AM, Kleer CG.

J Cell Sci. 2011 May 15;124(Pt 10):1752-8. doi: 10.1242/jcs.084194. Epub 2011 Apr 26.

49.

Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG.

Cancer Res. 2011 Mar 15;71(6):2360-70. doi: 10.1158/0008-5472.CAN-10-1933.

50.

EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development.

Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG.

Mod Pathol. 2011 Jun;24(6):786-93. doi: 10.1038/modpathol.2011.8. Epub 2011 Mar 11.

Supplemental Content

Loading ...
Support Center